Literature DB >> 8971561

Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours.

F F Chen1, J J Yan, K C Chang, W W Lai, R M Chen, Y T Jin.   

Abstract

Mcl-1 protein is a new member of the bcl-2 protein family. It is believed to be a blocker of apoptosis but might be different from bcl-2 in the control of apoptosis. Using immunostaining of formalin-fixed, paraffin-embedded sections, we investigated the expression of Mcl-1 in 42 thymic epithelial tumours: three medullary thymomas, five mixed thymomas, seven cortical thymomas, eight well-differentiated thymic carcinomas, 14 squamous cell carcinomas, four lymphoepithelioma-like carcinomas and one undifferentiated carcinoma, bcl-2 immunocytochemical localization was also performed for comparison. High-grade thymic carcinomas, especially squamous cell carcinomas, revealed more intense Mcl-1 immunoreactivity as compared to other subtypes (P < 0.001). In cases that co-expressed Mcl-1 and bcl-2, the less differentiated cells had more intense expression of bcl-2, while the more differentiated cells displayed stronger Mcl-1 immunoreactivity. The differential expression of Mcl-1 and bcl-2 in neoplastic cells provides evidence that these proteins may play different roles in the processes of programmed cell death in thymic neoplasms. The finding that thymic carcinomas have stronger immunoreactivity for Mcl-1 indicates that this protein could be a useful marker to differentiate aggressive thymic epithelial tumours from indolent ones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971561     DOI: 10.1046/j.1365-2559.1996.d01-540.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 2.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

3.  Clinicopathologic features and treatment of thymic lymphoepithelioma-like carcinoma: two case reports and literature review.

Authors:  Xin Guan; Di Zhang; Yang Han; Qingchang Li; Enhua Wang; Guangping Wu; Huanyu Zhao
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

4.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Authors:  I Petrini; P S Meltzer; P A Zucali; J Luo; C Lee; A Santoro; H S Lee; K J Killian; Y Wang; M Tsokos; M Roncalli; S M Steinberg; Y Wang; G Giaccone
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 8.469

5.  Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization.

Authors:  Gui Youn Lee; Woo Ick Yang; Hei Cheul Jeung; Sang Chul Kim; Min Young Seo; Chan Hee Park; Hyun Cheol Chung; Sun Young Rha
Journal:  BMC Genomics       Date:  2007-09-03       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.